|
Gene: GAS1 |
Gene summary for GAS1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GAS1 | Gene ID | 2619 |
Gene name | growth arrest specific 1 | |
Gene Alias | GAS1 | |
Cytomap | 9q21.33 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | P54826 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2619 | GAS1 | C30 | Human | Oral cavity | OSCC | 1.20e-02 | 8.53e-01 | 0.3055 |
2619 | GAS1 | C09 | Human | Oral cavity | OSCC | 2.96e-04 | 5.80e-01 | 0.1431 |
2619 | GAS1 | P4_S8_cSCC | Human | Skin | cSCC | 3.85e-02 | 5.53e-03 | -0.3095 |
2619 | GAS1 | P1_cSCC | Human | Skin | cSCC | 5.14e-13 | 8.50e-01 | 0.0292 |
2619 | GAS1 | P2_cSCC | Human | Skin | cSCC | 1.10e-09 | 4.65e-01 | -0.024 |
2619 | GAS1 | P4_cSCC | Human | Skin | cSCC | 1.22e-10 | 3.02e-01 | -0.00290000000000005 |
2619 | GAS1 | P10_cSCC | Human | Skin | cSCC | 1.32e-03 | 2.55e-01 | 0.1017 |
2619 | GAS1 | cSCC_p1 | Human | Skin | cSCC | 2.50e-06 | 2.81e-01 | -0.1916 |
2619 | GAS1 | cSCC_p11 | Human | Skin | cSCC | 9.43e-03 | 1.72e-01 | -0.2102 |
2619 | GAS1 | cSCC_p4 | Human | Skin | cSCC | 2.74e-04 | 1.31e-01 | -0.2022 |
2619 | GAS1 | cSCC_p8 | Human | Skin | cSCC | 3.77e-06 | 1.00e-01 | -0.1971 |
2619 | GAS1 | cSCC_p9 | Human | Skin | cSCC | 2.19e-12 | 1.53e-01 | -0.1991 |
2619 | GAS1 | ATC12 | Human | Thyroid | ATC | 2.02e-66 | 1.36e+00 | 0.34 |
2619 | GAS1 | ATC13 | Human | Thyroid | ATC | 1.34e-16 | 3.38e-01 | 0.34 |
2619 | GAS1 | ATC2 | Human | Thyroid | ATC | 4.11e-05 | 7.21e-01 | 0.34 |
2619 | GAS1 | ATC4 | Human | Thyroid | ATC | 5.26e-79 | 1.56e+00 | 0.34 |
2619 | GAS1 | ATC5 | Human | Thyroid | ATC | 1.80e-15 | 3.73e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
GO:00068888 | Oral cavity | OSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 97/7305 | 130/18723 | 1.42e-16 | 1.15e-14 | 97 |
GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
GO:00457864 | Oral cavity | OSCC | negative regulation of cell cycle | 206/7305 | 385/18723 | 4.28e-09 | 9.55e-08 | 206 |
GO:00459304 | Oral cavity | OSCC | negative regulation of mitotic cell cycle | 132/7305 | 235/18723 | 6.51e-08 | 1.16e-06 | 132 |
GO:004586120 | Oral cavity | OSCC | negative regulation of proteolysis | 181/7305 | 351/18723 | 1.01e-06 | 1.37e-05 | 181 |
GO:00164856 | Oral cavity | OSCC | protein processing | 121/7305 | 225/18723 | 4.56e-06 | 5.23e-05 | 121 |
GO:0060628 | Oral cavity | OSCC | regulation of ER to Golgi vesicle-mediated transport | 12/7305 | 15/18723 | 1.49e-03 | 7.13e-03 | 12 |
GO:00109552 | Oral cavity | OSCC | negative regulation of protein processing | 19/7305 | 29/18723 | 3.47e-03 | 1.47e-02 | 19 |
GO:19033182 | Oral cavity | OSCC | negative regulation of protein maturation | 19/7305 | 29/18723 | 3.47e-03 | 1.47e-02 | 19 |
GO:19033172 | Oral cavity | OSCC | regulation of protein maturation | 36/7305 | 67/18723 | 1.01e-02 | 3.51e-02 | 36 |
GO:00706132 | Oral cavity | OSCC | regulation of protein processing | 35/7305 | 65/18723 | 1.07e-02 | 3.64e-02 | 35 |
GO:0048193110 | Skin | cSCC | Golgi vesicle transport | 153/4864 | 296/18723 | 1.85e-21 | 3.41e-19 | 153 |
GO:0032386110 | Skin | cSCC | regulation of intracellular transport | 156/4864 | 337/18723 | 4.48e-16 | 3.96e-14 | 156 |
GO:000734617 | Skin | cSCC | regulation of mitotic cell cycle | 192/4864 | 457/18723 | 3.47e-14 | 2.31e-12 | 192 |
GO:000688810 | Skin | cSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 73/4864 | 130/18723 | 2.60e-13 | 1.57e-11 | 73 |
GO:005160419 | Skin | cSCC | protein maturation | 117/4864 | 294/18723 | 1.27e-07 | 2.93e-06 | 117 |
GO:004593014 | Skin | cSCC | negative regulation of mitotic cell cycle | 93/4864 | 235/18723 | 3.14e-06 | 4.89e-05 | 93 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GAS1 | SNV | Missense_Mutation | c.662N>T | p.Asp221Val | p.D221V | P54826 | protein_coding | tolerated(0.16) | possibly_damaging(0.684) | TCGA-67-4679-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GAS1 | SNV | Missense_Mutation | c.608N>T | p.Cys203Phe | p.C203F | P54826 | protein_coding | deleterious(0) | possibly_damaging(0.746) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GAS1 | SNV | Missense_Mutation | c.623N>G | p.Glu208Gly | p.E208G | P54826 | protein_coding | tolerated(0.08) | benign(0.039) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GAS1 | SNV | Missense_Mutation | c.788N>G | p.Asp263Gly | p.D263G | P54826 | protein_coding | tolerated(0.1) | benign(0.063) | TCGA-BR-8363-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GAS1 | SNV | Missense_Mutation | c.848N>T | p.Pro283Leu | p.P283L | P54826 | protein_coding | deleterious_low_confidence(0.02) | benign(0.001) | TCGA-CD-A487-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | epirubicin | CR | |
GAS1 | SNV | Missense_Mutation | c.796G>A | p.Asp266Asn | p.D266N | P54826 | protein_coding | deleterious(0.03) | possibly_damaging(0.886) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR | |
GAS1 | SNV | Missense_Mutation | novel | c.533N>A | p.Arg178His | p.R178H | P54826 | protein_coding | tolerated(0.12) | probably_damaging(0.993) | TCGA-IN-A7NT-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | leucovorin | SD |
GAS1 | SNV | Missense_Mutation | c.737N>G | p.Ala246Gly | p.A246G | P54826 | protein_coding | tolerated(0.13) | benign(0) | TCGA-EM-A3AL-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |